Health Policy Update: Impact of the 2024 U.S. Elections – Diagnosing Health Care
Watchful Waiting: Three Weeks Left in Lame Duck - Congress returns on Tuesday to begin the remaining three weeks of the lame duck session. Lawmakers have a packed agenda, and they have 18 days to pass a bill funding the...more
Congress returned to Washington this week with just five weeks left in this year’s legislative calendar. With a Continuing Resolution (CR) that expires December 20, 2024, either a year-end spending package or a new Continuing...more
Votes in the 2022 Midterm Elections are still being tallied. It will likely take several more days, if not weeks, to be able to confirm who will hold the majority in the House and Senate.Please note that House, Senate, and...more
On September 30, 2022, Congress enacted legislation to reauthorize the Food and Drug Administration (FDA) user fee programs for branded/reference drugs and biologics, medical devices, generic drugs and biosimilars (PDUFA,...more
With the presidential transition underway, we now look forward to what the Biden administration will seek to accomplish, particularly in the realm of health care policy. President-elect Biden has been clear that he wants to...more
In Washington: The possibility of a lame-duck session coronavirus relief deal remains shaky. House Speaker Nancy Pelosi (D-CA) holds out hope, telling reporters Thursday that she wants “as clean a slate as possible” for an...more
ML STRATEGIES PLANNING SERIES OF UPDATES ON THE CONGRESSIONAL AGENDA - Following up on our recent alert on the remaining legislative agenda for the “lame duck” session of the current 115th Congress, ML Strategies will be...more
GOVERNMENT FUNDING - This week, Congress is expected to pass a two - week extension to avoid a partial government shutdown . This means Congress will now have until December 21 st to pass a partial spending bill and wrap...more
Highlights this week: Democrats’ takeover of the House will yield big changes for healthcare policy in 2019; several GOP lawmakers active in healthcare policy are defeated; pharma pushes for Part D changes in the lame duck;...more